Gastrin-17 (G-17), pepsinogen-1 (Pg1) and 
INTRODUCTION
Gastroesophageal reflux disease (GERD) is characterised by abnormal excessive acidic gastric content reflux in esophagus and it has complex pathophysiology (Mulholland et al., 1989; Collen and Johnson, 1992; Abe et al., 2009) . Production of gastric acid is controlled by various physiological mechanisms, involving gastrin-17 (G-17) exclusively produced by the G cells located in the antral mucosa of stomach (Gritti et al., 2000; Dockray, 2004) . G-17 is crucial acid secretion stimulator, controlled via negative feedback mechanisms.
Pepsinogen-1 (Pg1), a precursor of pepsin, is produced by the chief and mucus cells located in the corpus mucosa of the stomach. Pepsinogen-2 (Pg2) is produced not only in the corpus mucosa, but also in antral and duodenal mucosa (Gritti et al., 2000) . Some studies have demonstrated different gastric acid exposure profiles among various forms of erosive reflux disease (Mulholland et al., 1989; Collen and Johnson, 1992) . Since the levels of these biomarkers reflect functional state of the gastric mucosa, they are used for non-invasive diagnosis and screening for atrophic gastritis (Kuipers, 2003; Vaananen et al., 2003; Pasechnikov et al., 2005; Iijima et al., 2009; Narsollahzadeh et al., 2011) . For PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 72 (2018 ), No. 3 (714), pp. 172-176. DOI: 10.2478 /prolas-2018 
NON-INVASIVE DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE USING GASTRIN-AND PEPSINOGEN-BASED TESTS
example, an increased level of G-17 may reflect atrophy of corpus mucosa or inflammation of antral mucosa, while a decreased G-17 level suggests atrophy of the antral mucosa. All of these biomarkers are involved in the secretion and production of the gastric acid, but it still remains unclear if there is any association among levels of biomarkers and gastroesophageal reflux disease.
The aim of the study was to clarify if Erosive reflux disease (ERD) or non-ERD (NERD) could be distinguished from other dyspeptic conditions in patients, in a non-invasive manner using G-17, Pg1, and Pg2 based tests.
MATERIALS AND METHODS

Study design.
Patients with various complaints concerning the side of upper gastrointestinal system, who visited the outpatient department of Rîga East Clinical University Hospital (Rîga, Latvia) and Centre of Digestive Diseases "GAS-TRO" (Rîga, Latvia) during the time period 2005-2011, were invited to participate in the study. In total 841 dyspeptic patients were interviewed and asked to fill in a special questionnaire about their complaints (heartburn, acid regurgitation, loss of appetite, postprandial fullness, early satiation, epigastric pain, vomitus and other), medical history (cancer anamnesis, previous operations etc.) and history of drug usage (proton pump inhibitors, Helicobacter pylori eradication therapy and histamine-2 antagonists).
In the questionnaire about patient complaints, the patients answered "yes" or "no" to all questions except those about heartburn and acid regurgitation (Table 1) . Dyspepsia was defined in accordance to the Rome III criteria as the presence of at least one of four cardinal dyspepsia symptoms (postprandial fullness, early satiation, epigastric pain or epigastric burning), in the absence of organic or metabolic disturbances likely to explain those symptoms (Tack et al., 2006) . After the interview a blood sample was taken from each patient and then upper gastrointestinal endoscopy with standard biopsy was performed.
The following inclusion criteria were used: dyspeptic patients identified as Rome III criteria, age at least 18 years, non-pregnant, willing to participate in the study and did not meet exclusion criteria.
The following exclusion criteria were used: use of proton pump inhibitors and/or histamine-2 antagonists during the last month, active ulcer disease, gastric cancer, gastric lymphoma, Barrett's esophagus (BE), hiatus hernia of esophagus and history of any type of gastric surgery.
According to the medical history and endoscopic finding, the patients (n = 673) were divided into three groups (Katz et al., 2013) : the ERD group consisted of patients with visible esophageal mucosa breaks (ulcers and/or erosions) elevated according to the Los Angeles classification (Lundell et al., 1999) , NERD patients were defined as having symptoms with known quality and duration (heartburn and/or acid regurgitation appearing at least twice a week for at least six months) and having no visible esophageal mucosa breaks (Dixon et al., 1996) , and a control group was composed of other patients with various complaints about the upper gastrointestinal system's side and having no evidence of any form of gastroesophageal reflux disease.
Levels of detected biomarkers and their ratios in the ERD and NERD study groups were compared to control patients. To clarify if changes in the levels of the biomarkers were influenced by underlying changes of gastric mucosa, the levels of the biomarkers and their ratios were compared among patient groups after exclusion of all patients having at least one potential condition that might modify the levels of the biomarkers (gastric corpus and antrum mucosa atrophy, Helicobacter pylori colonisation of gastric mucosa).
Plasma biomarkers.
A blood sample from each patient was taken after night fasting prior to upper gastrointestinal endoscopy or 24 hours after the procedure. Blood plasma was separated from the whole blood, frozen immediately and stored at -80°C in the laboratory. Then, levels of Pg1, Pg2 and G-17 was measured by specific enzyme linked immunosorbent assay (Pepsinogen-I EIA Test kit, Pepsinogen-II EIA Test kit and Gastrin-17 EIA Test kit, GastroPanel ® , Biohit Oyj., Helsinki, Finland) according to the manufacture's instructions. In addition the Pg1 and Pg2 ratio (Pg1/Pg2) was calculated.
Upper gastrointestinal tract endoscopy. Upper gastrointestinal tract endoscopy was done after night fasting. Presence of esophageal mucosa breaks (ulcers and/or erosions) was evaluated according to Los Angeles classification (Lundell et al., 1999) . Standard biopsy material from each patient was taken during the procedure from at least five different loci of the stomach in accordance to the updated Sydney system: two from corpus mucosa (one from the lesser and one from the greater curvature), one from incisura angularis mucosa (from the lesser curvature) and two from antrum mucosa (one from the lesser and one from the greater curvature) (Dixon et al., 1996) . Additional biopsies were taken from any columnar-lined mucosa of the lower part of esophagus.
Histopathology. An experienced expert gastrointestinal histopathologist (DJ), blinded from any clinical data, examined all of the biopsies. All findings were reported separately for each site of stomach: corpus, incisura angularis and antrum. Staining with haematoxylin and eosin was done for evaluation of gastric mucosa atrophy. Giemsa staining was used to determine density of Helicobacter pylori gastric mucosa colonisation.
The loss of appropriate glands with or without metaplastic epithelial transformation was defined as mucosa atrophy and was scored using visual analogue scales (0 = absent, 1 = mild, 2 = moderate, 3 = severe) (Dixon et al., 1996) .
Biopsies from the incisura angularis and antrum mucosa were considered as the antral mucosa. The highest score for estimated parameters was used in the analysis.
The diagnosis of Barrett's esophagus was made if the specialised metaplastic columnar epithelium with goblet and/or pre-goblet cells was confirmed by histopathological examination in biopsy samples taken from any columnar-lined mucosa of the lower part of esophagus.
Statistical analysis. Distribution of age was characterised using median and range. Frequency of gender is shown in per cents. Distribution of biomarkers and their ratio was characterised by median and interquartile range (IQR = Q 1 -Q 3 ). Bivariate comparison of medians of biomarker levels and their ratios between groups was done using the Mann-Whitney U test. Statistically significant difference was considered if the p-value was below 0.05. All analyses were generated using SPSS 20.0 (SPSS Inc., Chicago, IL, USA).
Ethical consideration. The local Committee of Ethics approved study protocol before patient recruitment was started. All patients signed an informed consent form prior the admission.
RESULTS
The final sample included 673 patients: 141 patients in the ERD group (median age 48 years (range 18-84), male/female ratio (M/F) -68/83); 122 patients in the NERD group (median age 45 years (range 18-78), M/F -32/90) and 410 patients in the control group (median age 50 years (range 18-90), M/F -97/313).
The distribution of ERD severity according to the Los Angeles classification (Lundell et al., 1999) Patients who after histopathological evaluation showed potential conditions that might modify levels of biomarkers were excluded from the study groups: 81 patients from the ERD group; 85 from the NERD group and 282 from the control group (Table 3 ).
The numbers of remaining patients were 60 in the ERD group, 37 in the NERD group and 128 in the control group. After exclusion of the above patients, median level of G-17 in the ERD group showed no difference compared to control patients (respectively, 0.81 pmol/l versus 0.74 pmol/l, p = 0.956). Levels of all other biomarkers and their ratios were not significantly different in ERD and NERD groups compared to control patients. The bivariate comparison of levels of biomarkers after exclusion of all potential conditions that might modify levels of biomarkers is shown in Table 4 .
DISCUSSION
Our study was focused on the evaluation of a possible alternative diagnostic method to distinguish GERD from other ERD, erosive reflux disease; NERD, non-erosive reflux disease; IQR, interquartile range; G-17, Gastrin-17; Pg1, Pepsinogen-1; Pg2, Pepsinogen-2 ERD, erosive reflux disease; NERD, non-erosive reflux disease patients with dyspepsia. Pathogenesis of GERD is linked to the functional state of gastric mucosa, so it was thought that measurement of biomarkers of gastric mucosa seemed to be a promising diagnostic tool.
In our study prior exclusion of the patients having conditions that may influence secretion of the biomarkers levels of G-17 and Pg2 were significantly lower and Pg1/Pg2 higher in the ERD group compared to the control group. However, after exclusion of all conditions (antrum and corpus mucosa atrophy, Helicobacter pylori colonisation of antrum mucosa) that may influence levels of biomarkers, significant differences were lost. A study by Malfertheiner's group on biomarker levels among various forms of GERD showed similar results for a study population that had a much lower rate of gastric mucosa atrophy and Helicobacter pylori colonisation (Monkemuller et al., 2008) .
No statistically significant difference among biomarker levels was observed between NERD and the control group before exclusion of all conditions that may influence biomarker levels, nor after exclusion of those conditions. However, in a study from Japan, NERD was linked with decreased level of Pg1/Pg2 (Fujiwara et al., 2005) . Another study from Japan found that both ERD and NERD patients had increased level of Pg1/Pg2 (Minatsuki et al., 2013) .
In our study almost all patients in the ERD group presented in the A or B esophagitis stage, which may have influenced the obtained results. However, a significant difference was also not observed in the levels of biomarkers in a matched case-control study (Monkemuller et al., 2008) .
Although BE is considered as a form of GERD, the sampled group in our study contained no BE patients. A lower level of G-17 (Sipponen et al., 2005) and higher level of Pg1 ) have been observed in BE patients.
On the one hand, levels of biomarkers are indirect indicators of the functional state of gastric mucosa, which is why they can be successfully used for non-invasive diagnostic of atrophic gastritis (Kuipers, 2003; Vaananen et al., 2003; Pasechnikov et al., 2005; Iijima et al., 2009; Narsollahzadeh et al., 2011) . On the other hand, this likely is not be the case for GERD patients (Peitz et al., 2011) . Our data support the idea that GERD is a complex disease and it has a very complex pathophysiology; probably, increased gastric acid secretion is not the most important pathophysiological mechanism in ERD and NERD.
The most important limitation of our study was that the control group was represented not by healthy individuals, but by patients with various complaints from the side of upper gastrointestinal system. It is known that the pattern of pepsinogen secretion varies among patients with functional dyspepsia (Yoshikawa et al., 2002) .
In summary, Pg1, Pg2, and G-17 based tests cannot be used to distinguish ERD or NERD from other dyspeptic patients. Also, ERD and NERD patients cannot be distinguished using serological tests only.
Considering the gastric acid secretion profile differs in BE compared to other patients, future studies should focus on clarifying the role of pepsinogen-based tests in the screening and diagnosis of BE. 
